Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Arcturus Therapeutics Holdings's enterprise value is $-30.21 Mil.
Arcturus Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-75.00 Mil. Therefore, Arcturus Therapeutics Holdings's EV-to-EBITDA for today is 0.40.
The historical rank and industry rank for Arcturus Therapeutics Holdings's EV-to-EBITDA or its related term are showing as below:
ARCT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -64.68 Med: -3.23 Max: 24.98
Current: 0.4
During the past 13 years, the highest EV-to-EBITDA of Arcturus Therapeutics Holdings was 24.98. The lowest was -64.68. And the median was -3.23.
ARCT's EV-to-EBITDA is ranked better than 88.56% of 402
companies
in the Biotechnology industry
Industry Median: 12.2
vs ARCT: 0.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arcturus Therapeutics Holdings's PE Ratio (TTM) for today is calculated as:
Arcturus Therapeutics Holdings's share price for today is $5.525.
Arcturus Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's EV-to-EBITDA falls into.
Arcturus Therapeutics Holdings's current Enterprise Value is $-30.21 Mil.
Arcturus Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-75.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings (ARCT) has a EV-to-EBITDA of 0.40 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Arcturus Therapeutics Holdings. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #46 out of 402 companies in the Biotechnology industry, placing it in the top 11.4%.
Is Arcturus Therapeutics Holdings' EV-to-EBITDA too high?
Arcturus Therapeutics Holdings' current EV-to-EBITDA is 0.40. The Biotechnology industry median EV-to-EBITDA is 12.20. Arcturus Therapeutics Holdings' value of 0.40 is 96.7% below this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #46 out of 402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' EV-to-EBITDA compare to MDWD and UNCY?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #46 out of 402 companies for EV-to-EBITDA. This places Arcturus Therapeutics Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.20. Arcturus Therapeutics Holdings' value of 0.40 is 96.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.20, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current EV-to-EBITDA of 0.40 is 96.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Arcturus Therapeutics Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 12.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current EV-to-EBITDA is 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.95, compared to a current price of $5.53 — trading 39.9% above its estimated fair value. The current EV-to-EBITDA is 0.40 and 96.7% below the Biotechnology industry median of 12.20. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current EV-to-EBITDA is 0.40 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued.
The current stock price of $5.53 is trading 39.9% above its estimated GF Value™ of $3.95.
GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.
Key valuation signals for ARCT:
EV-to-EBITDA: 0.40
GF Value™: $3.95 vs. price of $5.53 (39.9% above fair value)
Industry Position: 96.7% below the Biotechnology median (#46 of 402)
No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcturus Therapeutics Holdings Business Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score
Get the complete analysis for ARCT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCT has been successfully added to your 
